Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Seagen Inc. - Common Stock (NQ:SGEN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
SEAGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Seagen Inc. - SGEN
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting
From Seagen Inc.
Via Business Wire
News headline image
2 Excellent Dividend Stocks to Buy for Less Than $100 ↗
Both companies are steals at current levels. 
Via The Motley Fool
News headline image
Here's How Much You Would Have Made Owning Seagen Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Seagen Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
Analyst Ratings for Seagen ↗
 
Via Benzinga
News headline image
Second Quarter Outlook For Biotech Stocks ↗
Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. 
Via Talk Markets
News headline image
SGEN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Seagen Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
3 Low P/E Stocks That Will Double in One Year ↗
These are the low-PE stocks to buy and represent companies with strong fundamentals and cash flow potential. 
Via InvestorPlace
News headline image
Hedge Funds Fall Short: Underperforming Low-Cost S&P 500 ETF By 6% In 2023. Here's Why. ↗
So far, 2023 has not started well for the hedge fund sector, as a common SPDR S&P 500 Trust ETF (ARCA: SPY) fared much better than the Global X Guru Index ETF (ARCA: GURU), a fund that invests in the... 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
This Biotech's Stock Has Been Under Pressure, Could Upcoming Clinical Trials Of Its Nanotechnology-Based COVID Drug Candidate Be The Start Of An Upward March? ↗
A company that seems to have seen poor market sentiment lately is NanoViricides Inc. (NYSEAMERICAN: NNVC), a pharmaceutical company specializing in the development of nanomedicine drugs for treating... 
Via Benzinga
News headline image
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis ↗
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the... 
Via Benzinga
News headline image
Consider This Undervalued Pharma Giant Before Its Blockbuster Deal Closes ↗
Wall Street isn't showing one of pharma's most prominent players any love. 
Via The Motley Fool
News headline image
Seagen to Report First Quarter 2023 Financial Results on April 27, 2023
From Seagen Inc.
Via Business Wire
News headline image
Is Pfizer Stock a Buy, Sell or Hold? Here’s My Call. ↗
Pfizer can't depend on Covid-19 vaccines as a revenue source in 2023, but PFE stock can still grow as the drugmaker broadens its pipeline. 
Via InvestorPlace
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Univar Solutions Inc. (NYSE - UNVR), Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), U.S. Xpress Enterprises, Inc. (NYSE – USX)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer ↗
 
Via Benzinga
News headline image
FDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
News headline image
Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run ↗
Viking Therapeutics stock might in the midst of a historic run. 
Via The Motley Fool
News headline image
It's Not Tesla, Meta Or Nvidia — The Best Performing Large-Cap Stock In 2023 Is A Crypto Play ↗
The SPDR S&P 500 ETF Trust (NYSE: SPY) has seen a positive return in 2023. Several sectors are in the green so far this year, and many well-known stocks are among the biggest gainers. Here’s a look at... 
Via Benzinga
News headline image
Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer ↗
 
Via Benzinga
News headline image
3 Low P/E Stocks That Are Bound to Rebound This Year ↗
These are the low P/E stocks to buy at current levels for a sharp reversal rally in the coming quarters. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023 ↗
 
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Why Pfizer Likely Isn't Done With M&A After the Seagen Deal ↗
Pfizer's stock remains down despite its latest dealmaking, but it may only be a matter of time before it starts to rally. 
Via The Motley Fool
News headline image
3 Dividend Contenders to Buy Now for Long-Term Gains Later
Dividend stocks have a role to play in any portfolio, and this article highlights three dividend contenders that you can buy now to get long-term gains later 
Via MarketBeat
News headline image
Pfizer Has Another Blockbuster on the Horizon, but That's Not All ↗
The drugmaker continues to grab headlines for the right reasons. 
Via The Motley Fool
News headline image
1 Top Healthcare Stock That Could Make You Richer in the Next Decade ↗
The Pfizer of tomorrow will be larger and even more lucrative to hold than it is now. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.